Fierce Drug Dev Forum 2019 has ended
avatar for Marc Schwabish

Marc Schwabish

Senior Vice President, Business Development and U.S. Operations
Marc Schwabish leads BD and US Operations at Fusion Pharmaceuticals. Fusion is developing radiotherapeutics with its proprietary Fast-ClearTM Linker Technology and was spun-out of a radiopharmaceutical manufacturer in 2017 with a $46M Series A. Dr. Schwabish’s background spans across Biopharma, Finance, Consulting, and Science. He was previously Head of US Pharma BD&L at Bayer and at Eisai, had both BD and Alliance Management responsibilities. Marc worked in Healthcare Investment Banking, Pharma Strategy Consulting, and other Pharma/Biotech companies. Dr. Schwabish holds a Ph.D. in Biochemistry and Molecular Pharmacology from Harvard and a B.S. in Biology from Cornell.